Abstract:Cerebral ischemia (stroke) triggers a complex series of biochemical and molecular mechanisms that impairs the neurologic functions through breakdown of cellular integrity mediated by excitotoxic glutamatergic signalling, ionic imbalance, free-radical reactions, etc. These intricate processes lead to activation of signalling mechanisms involving calcium/calmodulin-dependent kinases (CaMKs) and mitogen-activated protein kinases (MAPKs) such as extracellular signal-regulated kinase (ERK), p38, and c-Jun N-terminal kinase (JNK). The distribution of these transducers bring them in contact with appropriate molecular targets leading to altered gene expression, e.g. ERK and JNK mediated early gene induction, responsible for activation of cell survival/damaging mechanisms. Moreover, inflammatory reactions initiated at the neurovascular interface and alterations in the dynamic communication between the endothelial cells, astrocytes and neurons are thought to substantially contribute to the pathogenesis of the disease. The damaging mechanisms may proceed through rapid nonspecific cell lysis (necrosis) or by active form of cell demise (apoptosis or necroptosis), depending upon the severity and duration of the ischemic insult. A systematic understanding of these molecular mechanisms with prospect of modulating the chain of events leading to cellular survival/damage may help to generate the potential strategies for neuroprotection. This review briefly covers the current status on the molecular mechanisms of stroke pathophysiology with an endeavour to identify potential molecular targets such as targeting postsynaptic density-95 (PSD-95)/N-methyl-d-aspartate (NMDA) receptor interaction, certain key proteins involved in oxidative stress, CaMKs and MAPKs (ERK, p38 and JNK) signalling, inflammation (cytokines, adhesion molecules, etc.) and cell death pathways (caspases, Bcl-2 family proteins, poly (ADP-ribose) polymerase-1 (PARP-1), apoptosis-inducing factor (AIF), inhibitors of apoptosis proteins (IAPs), heat shock protein 70 (HSP70), receptor interacting protein (RIP), etc., besides targeting directly the genes itself. However, selecting promising targets from various signalling cascades, for drug discovery and development is very challenging, nevertheless such novel approaches may lead to the emergence of new avenues for therapeutic intervention in cerebral ischemia.

The eleven stages of the cell cycle, with emphasis on the changes in chromosomes and nucleoli during interphase and mitosis

Pathophysiologic mechanisms of acute ischemic stroke: An overview with emphasis on therapeutic significance beyond thrombolysis

Signaling Pathways in Brain Ischemia: Mechanisms and Therapeutic Implications.

The nurse therapist in a rehabilitation setting.

Ischemic stroke: From pathological mechanisms to neuroprotective strategies

H+ titration studies on human hemoglobin.

Molecular targets in cerebral ischemia for developing novel therapeutics

Cell Death Pathways in Ischemic Stroke and Targeted Pharmacotherapy

Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives

Stroke: Molecular mechanisms and therapies: Update on recent developments

Understanding the Pathophysiology of Ischemic Stroke: The Basis of Current Therapies and Opportunity for New Ones

Pathophysiology of Focal Cerebral Ischemia: a Therapeutic Perspective

Inflammatory mechanisms in ischemic stroke: therapeutic approaches

Mechanisms of ischemic brain injury

Targeting Autophagy in Ischemic Stroke: from Molecular Mechanisms to Clinical Therapeutics

Mechanisms of neuronal cell death in ischemic stroke and their therapeutic implications

Fibrin digestion by thrombin: the significance of the arginyl and lysyl bonds.

Pathogenic mechanisms following ischemic stroke

Background and Therapeutic Approaches

Ischemic stroke and mitochondria: mechanisms and targets